Dianthus Therapeutics (DNTH) Assets (2017 - 2025)

Dianthus Therapeutics' Assets history runs 9 years deep, the most recent figure standing at $530.9 million for Q4 2025.

• On a quarterly basis, Assets rose 41.95% year-over-year to $530.9 million in Q4 2025; TTM through Dec 2025 was $530.9 million, a 41.95% increase from a year earlier, with the FY2025 full-year figure at $530.9 million, up 41.95% from the prior year.
• Assets retreated to $530.9 million in Q4 2025 per DNTH's latest filing, from $577.4 million in the prior quarter.
• Across five years, Assets topped out at $577.4 million in Q3 2025 and bottomed at $78.6 million in Q2 2023.
• The 5-year median for Assets is $200.3 million (2021), against an average of $258.7 million.
• Across the five-year window, Assets sank 57.07% in 2023 and surged 369.19% in 2024, its largest moves.
• Year by year, Assets stood at $189.9 million in 2021, then sank by 56.24% to $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then jumped by 108.47% to $374.0 million in 2024, then surged by 41.95% to $530.9 million in 2025.
• Per Business Quant, the three latest DNTH Assets figures stand at $530.9 million (Q4 2025), $577.4 million (Q3 2025), and $326.1 million (Q2 2025).